NeOnc insiders bet big on brain cancer drug ahead of key trial data, signaling a potential breakthrough.

NeOnc Technologies is drawing attention with significant insider buying ahead of interim data from its Phase 2a trial of NEO100, a drug designed to penetrate the blood-brain barrier to treat aggressive brain cancers like glioblastoma. CEO Amir Heshmatpour has invested nearly $1 million recently, signaling strong confidence in the trial's outcome. Success could revolutionize treatment for brain cancers and other central nervous system diseases. Meanwhile, biotech giants Eli Lilly, Novo Nordisk, and Regeneron continue to lead with late-stage clinical successes in metabolic, neurodegenerative, and immunology fields, highlighting a dynamic and evolving biotech sector.